Abbott Laboratories, seeking to sell investors on its proposed breakup, said a pharmaceutical spinoff may gain $4 billion in extra revenue from three new therapies and expanded uses of autoimmune drug Humira.
Illinois , whose comptroller said the state is in the worst financial position in its history, may face a risk premium that is about 11 percent above what it paid last month when it sells $900 million of Build America Bonds today.
Abbott Laboratories plans to invest more in research and development in emerging markets, Chief Executive Officer Miles White said. He spoke at a Financial Times pharmaceutical industry conference in London.
Abbott Laboratories, splitting into a drugmaker and a diversified health-care business, reported earnings that beat analysts’ estimates and raised its 2012 forecast as sales jumped more than expected for its top product.